research use only

Venetoclax (ABT-199) Bcl-2 inhibitor

Cat.No.S8048

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. This compound is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.
Venetoclax (ABT-199) Bcl-2 inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 868.44

Quality Control

Products Often Used Together with Venetoclax (ABT-199)

A-1210477

This compound and A-1210477 increase MCL1 expression and synergistically induce apoptosis in acute myeloid leukemia (AML) cells, MOLM13/MV4-11/SKM1/OCI-AML5.

Navitoclax (ABT-263)

It, Navitoclax and chemotherapy show promising efficacy and tolerability in patients with relapsed/refractory acute lymphoblastic leukemia.

S63845

It and S63845 significantly delay the time to viral rebound by 4-fold after antiretroviral therapy (ART) cessation in a humanized mouse model of HIV-1 infection.

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CS-THL1 Growth Inhibition Assay 20 nM 72 h DMSO Inhibits cell growth assessed by cell viability 25916698
CS-THL1 Apoptotic Assay 25 nM DMSO Induces apoptosis 25916698
DoGKiT Apoptotic Assay 50 nM DMSO Induces apoptosis 25916698
RS4-11 Growth Inhibition Assay 72 h IC50=0.0402 μM 25649768
NALM-6 Growth Inhibition Assay 72 h IC50>3 μM 25649768
SU-DHL-6 Growth Inhibition Assay 0.8 μM Inhibits cell growth assessed by cell viability 25590803
OCI-Ly19 Growth Inhibition Assay 1 μM Inhibits cell growth assessed by cell viability 25590803
SU-DHL-6 Function Assay 0.75 μM 18 h Increases pro-survival protein MCL-1 expression 25590803
KCL22 Function Assay 2 μM 48 h DMSO Increases DNA fragamentation 25333252
LOUCY Growth Inhibition Assay 10 μM 48 h DMSO IC50=0.0139 μM 25301704
ALL-SIL Growth Inhibition Assay 10 μM 48 h DMSO IC50=0.1803 μM 25301704
CUTLL1 Growth Inhibition Assay 10 μM 48 h DMSO IC50=0.3823 μM 25301704
KOPTK1 Growth Inhibition Assay 10 μM 48 h DMSO IC50=0.6432 μM 25301704
DND-41 Growth Inhibition Assay 10 μM 48 h DMSO IC50=1.9695 μM 25301704
PF-382 Growth Inhibition Assay 10 μM 48 h DMSO IC50=2.1824 μM 25301704
KARPAS-45 Growth Inhibition Assay 10 μM 48 h DMSO IC50=3.2225 μM 25301704
PEER Growth Inhibition Assay 10 μM 48 h DMSO IC50=4.6403 μM 25301704
CX-1 Growth Inhibition Assay 100 μM 72 h IC50=6.7 μM 25208882
LS147T Growth Inhibition Assay 100 μM 72 h IC50=29.5 μM 25208882
HL-60 Growth Inhibition Assay 48 h IC50<1 μM 24346116
MOLM-13 Growth Inhibition Assay 48 h IC50<1 μM 24346116
OCI-AML2 Growth Inhibition Assay 48 h IC50<1 μM 24346116
Kasumi-1 Growth Inhibition Assay 48 h IC50<1 μM 24346116
KG-1 Growth Inhibition Assay 48 h IC50<1 μM 24346116
THP-1 Growth Inhibition Assay 48 h IC50<1 μM 24346116
MOLM-14 Growth Inhibition Assay 48 h IC50<1 μM 24346116
MOLM-13 Apoptotic Assay 50 nM 24 h Apoptosis induction 24346116
HSB Growth Inhibition Assay 10 μM 48 h DMSO IC50=4.448 μM 24342948
MOLT4 Growth Inhibition Assay 10 μM 48 h DMSO IC50=4.154 μM 24342948
SKW-3/KE-37 Growth Inhibition Assay 10 μM 48 h DMSO IC50=0.712 μM 24342948
SUPT-11 Growth Inhibition Assay 10 μM 48 h DMSO IC50=4.473 μM 24342948
JURKAT Growth Inhibition Assay 10 μM 48 h DMSO IC50=4.893 μM 24342948
CCRF-CEM Growth Inhibition Assay 10 μM 48 h DMSO IC50=1.360 μM 24342948
LOUCY Apoptotic Assay 2 μM 48 h DMSO Apoptosis induction 24342948
RS4:11 Cytotoxicity assay 29407973
RS4:11 MTS assay 72 h 30278333
RS4:11 MTS assay 28926247
Toledo MTS assay 72 h 30278333
NCI60 SRB assay 48 h 27994761
RS4:11 MTT assay 24 h 29453135
melanoma SRB assay 48 h 27994761
leukemia SRB assay 48 h 27994761
renal cancer SRB assay 48 h 27994761
non-small cell lung cancer SRB assay 48 h 27994761
breast cancer SRB assay 48 h 27994761
colon cancer SRB assay 48 h 27994761
ovarian cancer SRB assay 48 h 27994761
CNS cancer SRB assay 48 h 27994761
prostate cancer SRB assay 48 h 27994761
Remb1 MTT assay 24 h 29453135
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 868.44 Formula

C45H50ClN7O7S

Storage (From the date of receipt)
CAS No. 1257044-40-8 Download SDF Storage of Stock Solutions

Synonyms GDC-0199 Smiles CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (115.14 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features
Re-engineered version of ABT-263 (Navitoclax).
Targets/IC50/Ki
Bcl-2 [1]
(Cell-free assay)
<0.01 nM(Ki)
In vitro
Venetoclax (ABT-199) shows less sensitivity to Bcl-xL, Mcl-1 and Bcl-w with Ki of 48 nM, > 444 nM and 245 nM, respectively. It potently inhibits FL5.12-Bcl-2 cells, RS4;11 cells with EC50 of 4 nM and 8 nM, while shows low activity against FL5.12-Bcl-xL cells with EC50 of 261 nM. This compound induces a rapid apoptosis in RS4;11 cells with cytochrome c release, caspase activation, the externalization of phosphatidylserine and the accumulation of sub-G0/G1 DNA. Quantitative immunoblotting reveals that sensitivity to it correlated strongly with the expression of Bcl-2, including NHL, DLBCL, MCL, AML and ALL cell lines. It also induces apoptosis in CLL with an average EC50 of 3.0 nM. [1]
Kinase Assay
Binding affinity assays
Binding affinities (Ki or IC50) of Venetoclax (ABT-199) against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Its binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. In this assay, Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and the compound at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
In vivo
Venetoclax (ABT-199) causes a maximal tumor growth inhibition of 95% and tumor growth delay of 152% in RS4;11 xenografts. It also inhibits xenograft growth (DoHH2, Granta-519) as a single agent or in combination with SDX-105 and other agents. [1]
References

Applications

Methods Biomarkers Images PMID
Western blot Mcl-1 / Bcl-xl / Bcl-2 / Bak / NOXA / Bim PARP / Cleaved PARP / Caspase 3 / Cleaved caspase3 / p-S6(Ser236/236) S8048-WB1 30663221
Growth inhibition assay Cell death Cell viability S8048-Growth1 28714472
Immunofluorescence Bcl-2 / Mcl-1 S8048-IF1 28767232

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06382168 Not yet recruiting
Leukemia Myeloid Acute
Delta-Fly Pharma Inc.
May 31 2024 Phase 1|Phase 2
NCT06263387 Not yet recruiting
AML Adult
French Innovative Leukemia Organisation|Acute Leukemia French Association
April 29 2024 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please offer some advice on the half-life of it ?

Answer:
According to the reference (https://www.ncbi.nlm.nih.gov/pubmed/24212376), its half-life in dogs is 12.9 hr.

Signaling Pathway Map